Literature DB >> 12160142

Non-cytotoxic therapies for malignant gliomas.

Umberto Basso1, Mario Ermani, Francesca Vastola, Alba A Brandes.   

Abstract

Malignant gliomas cause 2% of cancer deaths in western countries, and even the most intensive combinations of radiotherapy and chemotherapy cannot be curative. New chemotherapeutic drugs and alternative therapeutic modalities are strongly needed. Huge efforts are directed towards the development of innovative strategies for targeting and mending the specific molecular alterations in tumor cells (translational research). This review aims to summarize the most promising lines of investigational research in the field of neuro-oncology, such as non-cytotoxic drugs, immunotoxins, inhibitors of angiogenesis and gene therapy approaches, which will probably offer new therapy options for brain tumor patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12160142     DOI: 10.1023/a:1015839111005

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.506


  49 in total

1.  Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

Authors:  F Ciardiello; R Caputo; R Bianco; V Damiano; G Fontanini; S Cuccato; S De Placido; A R Bianco; G Tortora
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

2.  Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas.

Authors:  A A Brandes; E Scelzi; P Zampieri; A Rigon; A Rotilio; P Amista; F Berti; M V Fiorentino
Journal:  Am J Clin Oncol       Date:  1997-08       Impact factor: 2.339

3.  Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma.

Authors:  R W Rand; R J Kreitman; N Patronas; F Varricchio; I Pastan; R K Puri
Journal:  Clin Cancer Res       Date:  2000-06       Impact factor: 12.531

4.  Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.

Authors:  H A Fine; W D Figg; K Jaeckle; P Y Wen; A P Kyritsis; J S Loeffler; V A Levin; P M Black; R Kaplan; J M Pluda; W K Yung
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

Review 5.  Tyrosine kinase inhibitors-ZD1839 (Iressa).

Authors:  C L Arteaga; D H Johnson
Journal:  Curr Opin Oncol       Date:  2001-11       Impact factor: 3.645

6.  Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors.

Authors:  D W Laske; R J Youle; E H Oldfield
Journal:  Nat Med       Date:  1997-12       Impact factor: 53.440

7.  Inhibitory effects of CAI in glioblastoma growth and invasion.

Authors:  W Jacobs; T Mikkelsen; R Smith; K Nelson; M L Rosenblum; E C Kohn
Journal:  J Neurooncol       Date:  1997-04       Impact factor: 4.130

8.  Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate.

Authors:  Z Ram; D Samid; S Walbridge; E M Oshiro; J J Viola; J H Tao-Cheng; S Shack; A Thibault; C E Myers; E H Oldfield
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

9.  In vitro and in vivo cytotoxicity of gossypol against central nervous system tumor cell lines.

Authors:  T Coyle; S Levante; M Shetler; J Winfield
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

10.  Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.

Authors:  Kurt A Jaeckle; Kenneth R Hess; W K Alfred Yung; Harry Greenberg; Howard Fine; David Schiff; Ian F Pollack; John Kuhn; Karen Fink; Minesh Mehta; Timothy Cloughesy; M Kelly Nicholas; Susan Chang; Michael Prados
Journal:  J Clin Oncol       Date:  2003-06-15       Impact factor: 44.544

View more
  8 in total

1.  The present and future management of malignant brain tumours: surgery, radiotherapy, chemotherapy.

Authors:  R Rampling; A James; V Papanastassiou
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

Review 2.  Anti-angiogenic therapy in pediatric neuro-oncology.

Authors:  Mark W Kieran
Journal:  J Neurooncol       Date:  2005-12       Impact factor: 4.130

Review 3.  Microsurgery for malignant gliomas.

Authors:  M Gazi Yaşargil; Paulo A S Kadri; Dianne C H Yasargil
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

4.  Rejection of RG-2 gliomas is mediated by microglia and T lymphocytes.

Authors:  Christopher L Mariani; Joshua G Kouri; Wolfgang J Streit
Journal:  J Neurooncol       Date:  2006-04-13       Impact factor: 4.130

5.  Progesterone effects on cell growth of U373 and D54 human astrocytoma cell lines.

Authors:  Gabriela González-Agüero; Andrés A Gutiérrez; Diana González-Espinosa; José D Solano; Rocío Morales; Aliesha González-Arenas; Edith Cabrera-Muñoz; Ignacio Camacho-Arroyo
Journal:  Endocrine       Date:  2007-11-15       Impact factor: 3.633

6.  Bromodeoxyuridine inhibits cancer cell proliferation in vitro and in vivo.

Authors:  Lindsay H Levkoff; Gregory P Marshall; Heather H Ross; Maria Caldeira; Brent A Reynolds; Meryem Cakiroglu; Christopher L Mariani; Wolfgang J Streit; Eric D Laywell
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

7.  Nonspecific immunotherapy with intratumoral lipopolysaccharide and zymosan A but not GM-CSF leads to an effective anti-tumor response in subcutaneous RG-2 gliomas.

Authors:  Christopher L Mariani; Didier Rajon; Francis J Bova; Wolfgang J Streit
Journal:  J Neurooncol       Date:  2007-06-14       Impact factor: 4.130

Review 8.  Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside.

Authors:  Syed R Husain; Raj K Puri
Journal:  J Neurooncol       Date:  2003-10       Impact factor: 4.130

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.